SEARCH

SEARCH BY CITATION

References

  • 1
    Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 28996.
  • 2
    Hudes G, Carducci M, Choueiri T et al. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011; 9 (Suppl): S129.
  • 3
    Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 358490.
  • 4
    Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 227181.
  • 5
    Tomita Y, Shinohara N, Yuasa T et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010; 40: 116672.
  • 6
    Yuasa T, Tsuchya N, Urakami S et al. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Int 2012; 109: 134954.
  • 7
    Shinohara N, Abe T, Mochizuki T et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol 2011; doi:10.1016/j.urolonc.2011.08.009 [Epub ahead of print].
  • 8
    Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010; 57: 31725.
  • 9
    Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 83241.
  • 10
    Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 14608.
  • 11
    Sobin LH, Wittekind CH, eds. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley & Sons, Inc., 1997.
  • 12
    Japanese Urological Association, The Japanese Society of Pathology and Japanese Radiological Society. General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma, 4th edn. Tokyo: Kanehara, 2011.
  • 13
    Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 36187.
  • 14
    Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
  • 15
    Miyake H, Kurahashi T, Takenaka T, Inoue T, Fujisawa F. Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukin-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2009; 27: 598603.
  • 16
    Akaza H, Kawai K, Tsukamoto T et al. Successful outcomes using combination therapy of interleukin-2 and interferon-α for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol 2010; 40: 6849.